ContractResearch Collaboration, Option and License Agreement • February 24th, 2021 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]”.
Research Collaboration, Option and License Agreement Between Isis Pharmaceuticals, Inc. And Janssen Biotech Inc.Research Collaboration, Option and License Agreement • February 24th, 2021 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • New York
This RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of the 22nd day of December, 2014 (the “Effective Date”), by and between Isis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Isis”), and Janssen Biotech Inc., a Pennsylvania company, with principal offices located at 800/850 Ridgeview Road, Horsham, PA 19044 (“JBI”) JBI and Isis each may be referred to herein individually as a “Party” or collectively as the “Parties.” Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in Appendix 1. All attached appendices and schedules are a part of this Agreement.
IONIS PHARMACEUTICALS, INC. ADVISORY SERVICES AGREEMENT (“SUMMARY PAGE”)Advisory Services Agreement • February 24th, 2021 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • California
Duration of Advisory Services (the “Advisory Period”): An initial term beginning immediately following the June 2, 2021 Annual Stockholders Meeting and ending on June 30, 2023 unless extended or terminated in accordance with Section 8 of Exhibit A below.
IONIS PHARMACEUTICALS, INC. THIRD AMENDED AND RESTATED STRATEGIC ADVISORY SERVICES AGREEMENT (“SUMMARY PAGE”)Strategic Advisory Services Agreement • February 24th, 2021 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • California
This Third Amended and Restated Strategic Advisory Services Agreement is entered into by and between Lyme Pinnacle Consulting Inc., for the services of B. Lynne Parshall, and is made effective as of February 22, 2021, and amends and restates the Strategic Advisory Service Agreement dated January 15, 2018, as amended on March 22, 2019 and January 9, 2020, by and between B. Lynne Parshall and Ionis Pharmaceuticals, Inc. (“Ionis”).
AMENDMENT NO. 3Strategic Collaboration Agreement • February 24th, 2021 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 3 (the “Amendment”) to the Strategic Collaboration Agreement dated July 31, 2015, as previously amended by Amendment No. 1 dated October 18, 2018, and Amendment No. 2 dated April 30, 2020 (the “Agreement”), is made by and between
